{
    "clinical_study": {
        "@rank": "89085", 
        "arm_group": [
            {
                "arm_group_label": "AGS15E Dose Level 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AGS15E Dose Level 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AGS15E Dose Level 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AGS15E Dose Level 4", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AGS15E Dose Level 5", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AGS15E Dose Level 6", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to assess the safety, pharmacokinetics, immunogenicity and\n      anti-tumor activity of AGS15E in subjects with metastatic urothelial cancer who failed at\n      least one prior chemotherapy regimen for metastatic disease."
        }, 
        "brief_title": "ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Urothelial Cancer", 
        "detailed_description": {
            "textblock": "All subjects will receive a single intravenous infusion of AGS15E once weekly for 3 weeks of\n      every 4 weeks.  A cycle is 4 weeks.  Subjects will continue treatment until disease\n      progression, intolerability of AGS15E or consent withdrawal.\n\n      The study design will follow a modified Continual Reassessment Method (CRM).  A disease\n      assessment will be conducted every 8 weeks (Q8W) +/- 7 days until disease progression.\n\n      A data review team (DRT) will review cumulative unaudited data on an interim basis to\n      explore additional doses and/or schedules, or the expansion of existing cohorts. Doses\n      intermediate to those predefined in the protocol may be explored with DRT endorsement."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e.,\n             cancer of the bladder, renal pelvis, ureter, or urethra).\n\n          -  Must have failed at least one prior chemotherapy regimen for metastatic disease\n             and/or is unfit for cisplatin-based chemotherapy\n\n          -  Subjects must have measureable disease according to RECIST (version 1.1)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Life expectancy of \u2265 3 months\n\n          -  Adequate hematologic function\n\n          -  Adequate renal function\n\n          -  Adequate liver function\n\n          -  Gamma GT \u2264 1.5 x ULN (upper limit of normal)\n\n          -  Lipase within the normal range\n\n          -  Amylase \u2264 1.5 x ULN\n\n        Exclusion Criteria:\n\n          -  Preexisting sensory neuropathy Grade \u2265 2 or motor neuropathy Grade \u2265 2\n\n          -  Uncontrolled central nervous system metastases\n\n          -  Use of any investigational drug within 14 days or 5 half-lives prior to the first\n             dose of study drug Any anticancer therapy, including: small molecules, immunotherapy,\n             chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat\n             cancer within 14 days prior to the first dose of study drug\n\n          -  Any P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days prior to the\n             first dose of study drug\n\n          -  History of thromboembolic events and/or bleeding disorders \u2264 3 months (e.g., deep\n             vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study\n             drug\n\n          -  Positive Hepatitis B surface antigen test\n\n          -  Positive Hepatitis C antibody test\n\n          -  Decompensated liver disease as evidenced by clinically significant ascites refractory\n             to diuretic therapy, hepatic encephalopathy, or coagulopathy\n\n          -  History of a primary invasive malignancy not listed in the inclusion criteria, which\n             has not been in remission for at least 3 years.  The following are exempt from the 3\n             year limit:\n\n               -  Non-melanoma skin cancer;\n\n               -  adenocarcinoma of the prostate that has been surgically treated with a\n                  post-treatment PSA that is undetectable;\n\n               -  cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Pap\n                  smear; and\n\n               -  definitively treated, stage I/II ER+ breast cancer\n\n          -  Active infection requiring treatment \u22647 days before first dose of study drug\n\n          -  History of eye surgery within 6 months, presence of cataracts or other ocular\n             disorders significantly affecting vision\n\n          -  Condition or situation which, in the investigator's opinion, may put the subject at\n             significant risk, may confound the study results, or may interfere significantly with\n             subject's participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963052", 
            "org_study_id": "AGS15E-13-1"
        }, 
        "intervention": {
            "arm_group_label": [
                "AGS15E Dose Level 1", 
                "AGS15E Dose Level 2", 
                "AGS15E Dose Level 3", 
                "AGS15E Dose Level 4", 
                "AGS15E Dose Level 5", 
                "AGS15E Dose Level 6"
            ], 
            "description": "intravenous (IV) infusion", 
            "intervention_name": "AGS15E", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Metastatic Urothelial Cancer", 
            "Pharmacokinetics of AGS15E", 
            "AGS15E", 
            "ASG-15ME", 
            "AGS15E-13-1"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama at Birmingham (UAB) Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Smilow Cancer Center at Yale New Haven Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University Medical School"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Tisch Cancer Institute of Mt. Sinai School of Medicine"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 1H5"
                    }, 
                    "name": "British Columbia Cancer Agency"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre at Hamilton Health Sciences"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4N 3M5"
                    }, 
                    "name": "Sunnybrook Cancer Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer", 
        "overall_contact": {
            "email": "Clinical@Agensys.com", 
            "last_name": "Agensys Clinical Research and Development", 
            "phone": "424-280-5000"
        }, 
        "overall_official": {
            "affiliation": "Agensys, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 26 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Concentration at the end of infusion (CEOI)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Terminal or apparent terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Systemic clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Volume of distribution at steady state (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of  subsequent cycles up to an average of 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of Anti-Drug Antibody (ADA)", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 months"
            }, 
            {
                "description": "Incidence of tumor response defined as either a complete response (CR) or partial response (PR) per RECIST criteria (version 1.1) that should be confirmed \u2265 28 days later", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 months"
            }, 
            {
                "description": "Defined as the percentage of subjects who experience a best response of either CR or PR in that cohort.  CR and PR should be confirmed \u2265 28 days later.", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 months"
            }, 
            {
                "description": "Defined as the percentage of subjects who experience a best response of CR, PR or stable disease (SD)", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 26 months"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Agensys, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}